- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01516086
A 12-Week Study in Adult Subjects With Asthma
A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study to Replicate Efficacy of Nebulized Fluticasone Propionate (FP) in Adult Subjects With Partly Controlled and Uncontrolled Asthma
Studieoversigt
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
South Carolina
-
Rock Hill, South Carolina, Forenede Stater, 29732
- CU Pharmaceutical Research
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- A signed and dated written informed consent form prior to the conduct of any study procedures
- Males and females between ≥ 18 and ≤ 60 years old.
- Non-smoker for at least 1 year prior to Visit 1, with a smoking history of no more than 10 pack-years (e.g., 1 pack [20 cigarettes] per day for 10 years).
6.Ability to understand and comply with the protocol requirements (including completion of daily PEFR, PFT and ACQ), instructions and protocol-stated restrictions.
7.Women of child-bearing potential (WOCBP) must have a negative pregnancy test at the screening visit. WOCBP include: any female who has experienced menarche and is not post-menopausal (defined as amenorrhea for at least 12 consecutive months), or has not undergone surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation). Women who are using acceptable contraceptive medications or devices to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy) will be considered WOCBP.
WOCBP must agree to avoid becoming pregnant for the duration of the study by using adequate contraception at study entry and throughout the trial. Examples of adequate contraception include the following:
- Norplant
- Medroxyprogesterone acetate injection
- Oral contraception
- Double-barrier method (e.g., condom and spermicide)
Abstinence, with one of the above WOCBP will be advised to notify the Investigator of any changes in their pregnancy status or any change in contraceptive use.
8.Agreement by subject to abide by the study protocol and its restrictions.
Exclusion Criteria:
- Past or present disease, excluding asthma, which as judged by the investigator, may place the subject at increased risk of complications, interfere with study participation, or confound any of the study objectives These diseases include, but are not limited to cardiovascular disease, malignancy, gastrointestinal disease, hepatic disease, diabetes type I or uncontrolled diabetes, type II, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease (including, but not confined to chronic bronchitis, emphysema, bronchiectasis, COPD, eosinophilic bronchitis or pulmonary fibrosis).
- An upper or lower respiratory tract infection within 4 weeks of Visit 1 and prior to Visit 2
- A history of hypersensitivity to the study drug or its components, including albuterol as rescue medication.
- History of illegal drug or alcohol abuse within the past 5 years.
- Pregnant or lactating women.
- Use of > 8 inhalations per day of SABA on any two consecutive days from screening to randomization (Visits 1 and 2).
- Use of an investigational drug or device within 30 days prior to screening
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Fluticasonpropionat (FP) - arm 1
FP BID (to gange dagligt)
|
FP Inhalation BID
Andre navne:
|
Eksperimentel: Fluticasonpropionat (FP) - arm 2
FP BID
|
FP Inhalation BID
Andre navne:
|
Eksperimentel: Fluticasonpropionat (FP) - arm 3
FP BID
|
FP Inhalation BID
Andre navne:
|
Eksperimentel: Fluticasonpropionat (FP) - Arm 4
FP BID
|
FP Inhalation BID
Andre navne:
|
Eksperimentel: Fluticasonpropionat (FP) - Arm 5
FP BID
|
FP Inhalation BID
Andre navne:
|
Placebo komparator: Placebo - Arm 6
Placebo inhalation solution
|
FP Inhalation BID
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
FEV1 (Forced Expiry Volume in 1 second)
Tidsramme: FEV1 at Week 12
|
FEV1 at Week 12
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Peak Expiratory Flow Rate (PEFR)
Tidsramme: PEFR i uge 12
|
PEFR i uge 12
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Imtiaz Chaudry, Dey
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Luftvejssygdomme
- Sygdomme i immunsystemet
- Lungesygdomme
- Overfølsomhed, Øjeblikkelig
- Bronchiale sygdomme
- Lungesygdomme, obstruktiv
- Respiratorisk overfølsomhed
- Overfølsomhed
- Astma
- Lægemidlers fysiologiske virkninger
- Autonome agenter
- Agenter fra det perifere nervesystem
- Anti-inflammatoriske midler
- Dermatologiske midler
- Bronkodilatatorer
- Anti-astmatiske midler
- Respiratoriske midler
- Anti-allergiske midler
- Fluticason
- Xhance
Andre undersøgelses-id-numre
- 191-092
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Fluticasone Propionate (FP)
-
Immune Targeting Systems LtdAfsluttet
-
FHI 360Ministry of Health, UgandaAfsluttetHIV-testning og rådgivningUganda
-
Foresee Pharmaceuticals Co., Ltd.Afsluttet
-
CSL BehringAfsluttetHæmofili BForenede Stater, Japan, Israel, Østrig, Bulgarien, Frankrig, Tyskland, Italien, Den Russiske Føderation, Spanien
-
University of California, San FranciscoPopulation Services InternationalAfsluttetFamilie planlægningIndien
-
Fervent PharmaceuticalsICON plcAfsluttetVasomotoriske symptomer | OvergangsalderenForenede Stater
-
CSL BehringAfsluttetHæmofili BTyskland, Australien, Italien, Israel, Tjekkiet, Spanien, Frankrig, Canada, Østrig, Den Russiske Føderation
-
Foresee Pharmaceuticals Co., Ltd.RekrutteringFanconi AnæmiForenede Stater
-
CSL BehringAfsluttetHæmofili BForenede Stater, Australien, Japan, Frankrig, Filippinerne, Spanien, Tjekkiet, Israel, Canada, Tyskland, Østrig, Bulgarien, Italien, Malaysia, Sydafrika
-
Five Prime Therapeutics, Inc.Worldwide Clinical TrialsTrukket tilbageEndometriecancer med FGFR2-mutationer